Physician profile
Jeffrey M Maher
NPI 1386649234
$7,120.48
in general payments reported to CMS, 2019-2025
21 companies · $2,561 in 2025
The $2,561 reported for 2025 was more than what 90% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $735 · 2020: $190 · 2021: $336 · 2022: $387 · 2023: $1,747 · 2024: $1,165 · 2025: $2,561.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,473.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,472.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $3,541.69 | 2022-2025 | Clareon, Centurion, Hydrus Microstent |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $694.27 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $594.89 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Johnson & Johnson Surgical Vision, INC. | $521.98 | 2021-2025 | Tecnis Simplicity, Tecnis Iol, Tecnis Iol |
| Abbvie INC. | $486.85 | 2022-2025 | |
| Harrow Eye, LLC | $242.72 | 2025 | Verkazia, Flarex, Tobradex St |
| Carl Zeiss Meditec USA, INC. | $203.66 | 2025 | Veracity Surgical |
| Rxsight INC | $144.11 | 2025 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Light Adjustable Lens (Lal) |
| Mallinckrodt Hospital Products INC. | $115.83 | 2023-2024 | Acthar |
| Aerie Pharmaceuticals, INC. | $111.22 | 2019 | |
| Novartis Pharmaceuticals Corporation | $99.98 | 2019-2023 | |
| Shire North American Group INC | $86.82 | 2019 | |
| Allergan, INC. | $53.88 | 2020-2022 | |
| Ocular Therapeutix, INC. | $50.26 | 2021-2023 | Dextenza |
| Kala Pharmaceuticals, INC. | $39.28 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Thea Pharma INC. | $37.77 | 2023-2024 | Iyuzeh |
| Sun Pharmaceutical Industries INC. | $30.92 | 2019-2020 | |
| Horizon Therapeutics Plc | $21.95 | 2023 | Tepezza |
| Oyster Point Pharma, INC. | $14.41 | 2023 | Tyrvaya |
| Biotissue Holdings INC. | $14.09 | 2020 | |
| Eyevance Pharmaceuticals LLC | $13.90 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Maher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.